Meet an Unreasonable Venture
Craif
Realising a society where people can live out their natural lives.
Notable Achievements
- Raised over US$33 million including equity, debt and grants
- Launched miSignal", a multiple early cancer detection test in Japan, with annual sales growth of 500-600%
- Pancreatic cancer clinical trial for PMDA (equivalent to FDA) approval to start in 2024
Currently Operating in One Region
Press Mentions
April 29, 2025
Craif Secures $22M for Early Cancer Detection Technology - The Singular Ai
Craif, an innovative startup focused on early cancer detection, has successfully secured $22 million in funding. This investment will enable Craif to expand its groundbreaking urine biopsy...
Read on The Singular Ai »
April 28, 2025
Early cancer detection startup Craif raises $22M
Cancer ranks as one of the top causes of death worldwide. The National Cancer Institute reported nearly 20 million new cancer cases and 9.7 million
Read on TechCrunch »
May 27, 2024
Unreasonable Impact announces new roster of ventures for Asia Pacific programme
The story discusses the launch of a new online platform called "The Good Influence" that aims to promote positive content and combat misinformation on social media. It highlights the platform's...
Read on WebWire »
May 23, 2024
Unreasonable Impact announces new roster of ventures for Asia Pacific programme
Singapore, Friday 24 May 2024: Unreasonable Impact, a strategic partnership between Unreasonable Group and Barclays, has announced the latest ventures to join its Asia Pacific programme. This...
Read on Unreasonable »
July 11, 2023
Israeli climate-tech delegation visits UK House of Lords - ISRAEL21c
Reps from 10 startups spend four days meeting with British executives, investors and policymakers in collaborative events and discussions.
Read on ISRAEL21c »More Ventures in Health
Get the Unreasonable Newsletter
Get monthly updates on Craif and all of the other ventures working to solve the world's toughest problems.